Roche
Global healthcare company applying AI-designed gene-therapy vectors through its collaboration with Dyno Therapeutics.
- Company type
- Global pharmaceutical company
- Headquarters
- Basel, Switzerland
- Website
- https://www.roche.com
- Profile last verified
- 2026-07-29
AI Partnerships & Deployments
- 2024-10-24 — AAV gene-therapy vector collaboration with Dyno Therapeutics (Dyno Therapeutics). Roche's second collaboration with Dyno Therapeutics (the first was announced in October 2020), using Dyno's AI-powered CapsidMap platform to design novel AAV vectors for gene therapies targeting neurological diseases. Roche paid $50 million upfront, with Dyno eligible for over $1 billion in potential milestones plus royalties on net sales. Disclosed: $50M upfront; over $1B in potential milestones, plus royalties on net sales. Source: Business Wire (Dyno Therapeutics release) (accessed 2026-07-29)